-
2025.4.30
Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer.
著者 Hashimoto K, Kaira K, Mouri A, Shiono A, Miura Y, Yamaguchi O, Imai H, Kagamu H, Kuji I.
Transl Lung Cancer Res. 2025 Apr 30;14(4):1242-1253. doi: 10.21037/tlcr-2024-1084. Epub 2025 Apr 27.
PMID: 40386730
-
2025.4.1
A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab.
著者 Mouri A, Imai H, Endo S, Nakagawa J, Tsukamoto K, Kurata Y, Yamaguchi O, Masaki K, Hashimoto K, Shiono A, Miura Y, Kobayashi K, Kaira K, Kagamu H.
Cancer Med. 2025 Apr;14(8):e70741. doi: 10.1002/cam4.70741.
PMID: 40249663
-
2025.2.1
Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer.
著者 Matsukida A, Imai H, Shiono A, Ryuno Y, Hashimoto K, Miura YU, Endo S, Okazaki S, Yamaguchi OU, Mouri A, Abe T, Kaira K, Kobayashi K, Kato S, Kagamu H.
Anticancer Res. 2025 Feb;45(2):733-741. doi: 10.21873/anticanres.17461.
PMID: 39890195
-
2025.1.23
Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
著者 Endo S, Imai H, Mouri A, Tsukamoto K, Masaki K, Hashimoto K, Miura Y, Shiono A, Yamaguchi O, Nakagawa J, Kaira K, Kobayashi K, Kagamu H.
J Cancer Res Clin Oncol. 2025 Jan 23;151(1):43. doi: 10.1007/s00432-025-06089-x.
PMID: 39843575
-
2024.12.4
Concurrent Onset of Osimertinib-Induced Heart Failure and Metronidazole-Induced Encephalopathy During Brain Abscess Treatment: A Report of a Rare Case.
著者 Mikami E, Hashimoto K, Kaira K, Mouri A, Miura Y, Shiono A, Yamaguchi O, Imai H, Kagamu H.
Cureus. 2024 Dec 4;16(12):e75079. doi: 10.7759/cureus.75079. eCollection 2024 Dec.
PMID: 39759665
-
2024.11.18
Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer.
著者 Hashimoto K, Kaira K, Imai H, Yamaguchi O, Mouri A, Shiono A, Miura Y, Kobayashi K, Kagamu H, Kuji I.
Cancer Imaging. 2024 Nov 18;24(1):157. doi: 10.1186/s40644-024-00800-w.
PMID: 39558409
-
2024.9.15
Prognostic significance of LAT1 expression in pleural mesothelioma.
著者 Taguchi R, Kaira K, Miura Y, Umesaki T, Mouri A, Imai H, Kagamu H, Yasuda M, Kanai Y, Nitanda H, Ishida H, Sakaguchi H.
Heliyon. 2024 Sep 3;10(17):e37414. doi: 10.1016/j.heliyon.2024.e37414. eCollection 2024 Sep 15.
PMID: 39290273
-
2024.9.1
A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.
著者 Shiono A, Imai H, Endo S, Katayama K, Sato H, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.
Radiol Oncol. 2024 Sep 15;58(3):432-443. doi: 10.2478/raon-2024-0054. eCollection 2024 Sep 1.
PMID: 39287161
-
2024.8.5
The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.
著者 Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Masubuchi T, Kobayashi K, Minato K, Kato S, Kagamu H.
Oncology. 2025;103(2):83-93. doi: 10.1159/000540651. Epub 2024 Aug 5.
PMID: 39102792
-
2024.9.3
Prognostic significance of LAT1 expression in pleural mesothelioma.
著者 Taguchi R, Kaira K, Miura Y, Umesaki T, Mouri A, Imai H, Kagamu H, Yasuda M, Kanai Y, Nitanda H, Ishida H, Sakaguchi H.
Heliyon. 2024 Sep 3;10(17):e37414. doi: 10.1016/j.heliyon.2024.e37414. eCollection 2024 Sep 15.
PMID: 39290273 Free PMC article.
-
2024.9.1
A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.
著者 Shiono A, Imai H, Endo S, Katayama K, Sato H, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.
Radiol Oncol. 2024 Sep 15;58(3):432-443. doi: 10.2478/raon-2024-0054. eCollection 2024 Sep 1.
PMID: 39287161 Free PMC article. Review.
-
2024.8.5
The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.
著者 Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Masubuchi T, Kobayashi K, Minato K, Kato S, Kagamu H.
Oncology. 2024 Aug 5:1-11. doi: 10.1159/000540651. Online ahead of print.
PMID: 39102792
RESEARCH 研究の報告
